CORRESPONDENCE

High flow nasal cannula compared with conventional oxygen therapy for acute hypoxemic respiratory failure



© 2019 Springer-Verlag GmbH Germany, part of Springer Nature

Dear Editor,

We read the recent article written by Rochwerg et al. in *Intensive Care Medicine* and greatly appreciate their efforts to assess the effect of high flow nasal cannula (HFNC) for acute hypoxemic respiratory failure in a systematic review and meta-analysis [1]. Nevertheless, some issues should be further discussed.

First, it is obvious that $I^2 = 0$ in Fig. 3, why not apply the fixed effect model in meta-analysis and trial sequential analysis (TSA) [2, 3]? Second, they only performed TSA on invasive mechanical ventilation outcome and mortality outcome. But another major positive outcome of escalation of therapy was not evaluated by TSA. Third, The relative risk reduction = $\frac{\text{Incidence in control arm} - \text{incidence in intervention arm}}{\text{Incidence in control arm}}$ [4]. Therefore, the relative risk reduction of invasive mechanical ventilation outcome should be 16.58% $\left(\frac{\frac{235}{205} - \frac{205}{805}}{\frac{235}{805}}\right)$, not 15%. While, the relative risk reduction of

mortality outcome should be $4.60\% \left(\frac{\frac{186}{685} - \frac{187}{722}}{\frac{186}{685}}\right)$, not 15%,

too. Therefore, they cannot apply the same relative risk reduction (15%) to TSA of different outcomes. In addition, boundary required information size (RIS) on mortality outcome is ignored by Trial Sequential Analysis v.0.9.5.10 Beta

¹ Department of Anesthesiology, Zhongshan Hospital of Traditional Chinese Medicine, Affiliated to Guangzhou University of Chinese Medicine, 3 Kangxin Road, Zhongshan 528400, Guangdong, China ² Department of Otorhinolaryngology, The Second Affiliated

Full author information is available at the end of the article



due to little information used (0.92%). Therefore, TSA of mortality outcome cannot be drawn on principle.

Electronic supplementary material

The online version of this article (https://doi.org/10.1007/s00134-019-05652-8) contains supplementary material, which is available to authorized users.

Abbreviations

HFNC: High flow nasal cannula; TSA: Trial sequential analysis; RIS: Required information size.

Author details

¹ Department of Anesthesiology, Zhongshan Hospital of Traditional Chinese Medicine, Affiliated to Guangzhou University of Chinese Medicine, 3 Kangxin Road, Zhongshan 528400, Guangdong, China. ² Department of Otorhinolaryngology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, 88 Jiefang Road, Hangzhou 310009, Zhejiang, China.

Acknowledgements

We are grateful to Dr. Hui-zi Li for his statistical support for the study.

Compliance with ethical standards

Conflicts of interest

The authors declare that they have no competing interest.

Ethical approval

Not applicable

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Accepted: 20 May 2019

Published online: 3 June 2019

References

 Rochwerg B, Granton D, Wang DX, Helviz Y, Einav S, Frat JP, Mekontso-Dessap A, Schreiber A, Azoulay E, Mercat A, Demoule A, Lemiale V, Pesenti A, Riviello ED, Mauri T, Mancebo J, Brochard L, Burns K (2019) High flow



^{*}Correspondence: hgj719471594@zju.edu.cn; lunwuzhongshan@ outlook.com

Hospital, School of Medicine, Zhejiang University, 88 Jiefang Road, Hangzhou 310009, Zhejiang, China

nasal cannula compared with conventional oxygen therapy for acute ypoxemicrespiratory failure: a systematic review and meta-analysis. Intensive Care Med 45(5):563–572. https://doi.org/10.1007/s00134-019-05590 -5

- 2. Higgins JP, Green S (2011) Cochrane handbook for systematic reviews of interventions. Version 5.1.0. The Cochrane Collaboration
- 3. Barbateskovic M, Marker S, Granholm A, Anthon CT, Krag M, Jakobsen JC, Perner A, Wetterslev J, Moller MH (2019) Stress ulcer prophylaxis with

proton pump inhibitors or histamin-2 receptor antagonists in adult intensive care patients: a systematic review with meta-analysis and trial sequential analysis. Intensive Care Med 45:143–158

4. Schoenfeld P (2004) Evidence based medicine (EBM) in practice: applying relative risk and relative risk reduction. Am J Gastroenterol 99:2084–2085